Physician profile
Gary E Myerson
NPI 1346282399
$1,017,480.32
in general payments reported to CMS, 2019-2025
35 companies · $219K in 2025
The $219K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262K · 2020: $71K · 2021: $58K · 2022: $111K · 2023: $105K · 2024: $191K · 2025: $219K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $411K · Travel and Lodging: $88K · Food and Beverage: $16K · Education: $77.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $410,820.00 |
| Travel and Lodging | $88,313.37 |
| Food and Beverage | $15,946.37 |
| Education | $77.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $483,557.90 | 2019-2025 | Evenity, Otezla, Prolia |
| Astrazeneca Pharmaceuticals Lp | $156,471.20 | 2021-2025 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $99,627.64 | 2023-2025 | Strensiq |
| Pfizer INC. | $72,241.87 | 2019-2022 | |
| Radius Health, INC. | $66,108.88 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $30,313.01 | 2019-2022 | |
| Lilly USA, LLC | $24,787.74 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $23,188.43 | 2021-2023 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $16,481.94 | 2019-2022 | |
| Glaxosmithkline, LLC. | $15,527.25 | 2019-2024 | Nucala, Benlysta |
| Celgene Corporation | $14,478.84 | 2019 | |
| Abbvie INC. | $6,001.33 | 2019-2022 | |
| Gilead Sciences, INC. | $5,248.21 | 2019-2020 | |
| Ucb, INC. | $1,470.07 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $470.66 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $287.50 | 2021 | |
| Janssen Biotech, INC. | $254.43 | 2019-2022 | |
| Medexus Pharma, INC. | $177.16 | 2019-2020 | |
| Genzyme Corporation | $122.84 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $108.81 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.37 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $64.75 | 2019 | |
| Sanofi-Aventis U.S. LLC | $58.61 | 2019 | |
| Pacira Therapeutics, INC. | $57.94 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $53.36 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $45.94 | 2019 | |
| Ani Pharmaceuticals, INC. | $44.53 | 2022 | |
| Genentech USA, INC. | $32.57 | 2019-2020 | |
| Sobi, INC | $27.12 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.97 | 2025 | Acthar |
| Kiniksa Pharmaceuticals, Ltd. | $18.19 | 2023 | Arcalyst |
| Ferring Pharmaceuticals INC. | $15.67 | 2019 | |
| Organon LLC | $14.74 | 2022 | |
| Zyla Life Sciences, INC. | $12.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Myerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.